Osbon Capital Management’s Pfizer PFE Stock Holding History

Osbon Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.3K	Buy	1,341 +360	+37%	+$9.42K	0.03%	157
2026 Q1	$27.5K	Buy	+981	New	+$26.1K	0.02%	197

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Osbon Capital Management's PFE Position: Q2 2026 in Review

Osbon Capital Management increased its Pfizer (PFE) stake by 37% in Q2 2026, buying an estimated $9.42K and bringing the position to 1,341 shares worth $32.3K. The position accounts for 0.03% of the portfolio, ranked #157.

Osbon Capital Management first reported a position in PFE in Q1 2026 and has held it in 2 quarters since. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Osbon Capital Management held 1,341 shares of Pfizer worth $32.3K as of Q2 2026.
Osbon Capital Management bought 360 Pfizer shares in Q2 2026, an estimated $9.42K.
Pfizer made up 0.03% of Osbon Capital Management's portfolio in Q2 2026, its #157 holding.
Osbon Capital Management first reported a position in Pfizer in Q1 2026 and has held it in 2 quarters since.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Osbon Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.